Need for Process Innovation and Increased Manufacturing Complexity Driven by the Spread of Next-Generation Modalities

Cytiva, under Danaher, has identified that traditional batch manufacturing processes centered on monoclonal antibodies (mAbs) are facing limitations due to the rapid growth of next-generation biopharmaceutical modalities, such as antibody-drug conjugates (ADCs) and synthetic peptides. For marketed high-performance ADCs like Enhertu (fam-trastuzumab deruxtecan), maintaining ultra-high purity and ensuring operator safety during the conjugation process of highly toxic payloads and linkers has emerged as a critical challenge. In particular, to suppress non-target cytotoxicity, precise control of the Drug-to-Antibody Ratio (DAR) is required, making flexible, closed modular systems essential instead of standardized single-batch facilities. These technical barriers are driving global pharmaceutical companies to adopt proven specialized solutions instead of building their own facilities.

Acceleration of Single-Use Technology Adoption in High-Difficulty Chemical Synthesis and Purification Processes

As demand for marketed GLP-1/GIP receptor agonist peptide drugs, such as Mounjaro (tirzepatide), surges, resolving bottlenecks in large-scale liquid/solid-phase peptide synthesis (LPPS/SPPS) and chromatography purification has become urgent. Cytiva is expanding its supply of Single-Use Systems and the ÄKTA purification platform to drastically reduce validation periods and completely prevent the risk of cross-contamination. While existing stainless steel reactors require weeks for cleaning and residue verification, gamma-irradiated closed single-use bags and flow components enable small-batch, multi-product production and rapid batch changeovers. Consequently, the value of manufacturing infrastructure that preemptively prevents delays in approvals and massive rework losses due to drug impurity control failures is being maximized.

Technological Oligopoly in the Global Bioprocessing Value Chain and Regulatory Compliance

Global regulatory agencies, such as the US FDA and the European EMA, are applying extremely strict Chemistry, Manufacturing, and Controls (CMC) inspection standards during the marketing authorization review of advanced complex biologics. Accordingly, a few global equipment leaders, including Cytiva, Thermo Fisher Scientific (TMO), and Sartorius (SRT.DE), are expanding their market dominance by standardizing process validation data. From the perspective of drug developers, preemptively adopting regulatory-friendly and proven equipment packages is essential to prevent data supplement requests that may occur during Phase 3 and Biologics License Application (BLA) stages. Ultimately, the technical maturity of not only original drug developers but also process solution providers is becoming a decisive factor in the commercialization of new drugs.

Restructuring of the CDMO Ecosystem and Structural Growth in Bio-Materials and Equipment Investment

Large Contract Development and Manufacturing Organization (CDMO) companies, such as Lonza Group (LONN.SW) and Samsung Biologics (207940.KS), are making significant capital expenditures (CAPEX) to expand production lines for complex formulations. Next-generation modalities are evolving away from traditional ultra-large-scale culture tanks of over 10,000 liters toward precision processes based on high-yield, miniaturized single-use bioreactors. This solidifies a stable lock-in revenue structure for bio-materials and equipment companies that absorb the full benefits of global biopharmaceutical market growth without directly bearing the risks of clinical pipeline success or failure. As a result, supply chain partners that preemptively secure process technology standards will lead the structural super-cycle of the overall biopharmaceutical industry.